Effect of dapagliflozin on cardiac function and metabolic and hormonal responses to exercise.

Roselle A Herring,Iain Parsons,Fariba Shojaee-Moradie,Mary Stevenage,Nicola Jackson,Ralph Manders,A Margot Umpleby,Barbara A Fielding,Melanie Davies,David L Russell-Jones

DOI: https://doi.org/10.1210/clinem/dgac617

2022-10-24

Abstract:Objective To investigate the effect of SGLT2 inhibitor, dapagliflozin on cardiac function and the metabolic and hormonal response to moderate exercise in people with type 2 diabetes. Research, Design & Methods This was a double-blind placebo-controlled crossover study with a 4-week washout period. Nine participants were randomised to receive either 4 weeks of dapagliflozin or 4 weeks of placebo. After each treatment, they underwent an exercise protocol with two consecutive 10 min stages at a constant load corresponding to 40 and 70% VO2 max, coupled with hormonal and metabolic analysis. A blinded transthoracic echocardiogram was performed 3 days later. Results During the exercise protocol glucose and lactate were lower (p < 0.0001, p < 0.05 respectively) and β-hydroxybutyrate (BOBH) and growth hormone (GH) were higher (p < 0.0005, p = 0.01) following dapagliflozin treatment compared to placebo. There was a trend for lower insulin with dapagliflozin. Adrenalin, noradrenalin and glucagon were not different. Following dapagliflozin participants demonstrated an increased mean peak diastolic mitral annular velocity (e') in comparison to placebo (p = 0.03). The indexed left atrial volume and right ventricular e' were reduced following dapagliflozin compared with placebo (p = 0.045, p = 0.042 respectively). Arterial stiffness was not different between treatments (dapagliflozin 9.35 ± 0.60m/s; placebo 9.07 ± 0.72 m/s). Conclusions During exercise GH may be more important than catecholamines in driving the shift from glucose to fatty acid metabolism by SGLT2 inhibitors. The 4-week crossover design showed changes in cardiac function were rapid in onset and reversible.

endocrinology & metabolism